This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed at $0.24 in the latest trading session, marking a +1.04% move from the prior day.
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $0.26, moving -0.54% from the previous trading session.
Actinium (ATNM) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Actinium (ATNM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Tilray (TLRY) in Focus: Stock Moves 9% Higher
by Zacks Equity Research
Tilray (TLRY) shares rose 9% in the last trading session, amid huge volumes.
What Makes Actinium (ATNM) a New Buy Stock
by Zacks Equity Research
Actinium (ATNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.
What Makes Actinium (ATNM) a New Buy Stock
by Zacks Equity Research
Actinium (ATNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Has Actinium Pharmaceuticals (ATNM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Do Options Traders Know Something About Actinium (ATNM) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Actinium (ATNM) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for October 16th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 16th:
Top Ranked Momentum Stocks to Buy for October 15th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 15th:
PTC Therapeutics (PTCT) Jumps: Stock Rises 12.9%
by Zacks Equity Research
The shares of PTC Therapeutics (PTCT) rose nearly 13% yesterday.
Zacks.com featured highlights include: Western Digital, Hecla Mining, Sphere 3D, Actinium Pharmaceuticals and Southern National Bancorp
by Zacks Equity Research
Zacks.com featured highlights include: Western Digital, Hecla Mining, Sphere 3D, Actinium Pharmaceuticals and Southern National Bancorp
Beat the Market with Rising P/E Technique
by Zacks Equity Research
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
Actinium Posts Positive DMC View on Lomab-B Phase III Trial
by Zacks Equity Research
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.